Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Table 2

From: Hopkins Lupus Cohort: assessment of treatment effects

  Subgroup Thrombotic events Rate of events/1,000 person-years Rate ratios (95% CI) P value
Current prednisone None 52 10.6 1.0 (Ref. Gp)  
  1 to 9 mg/day 40 16.4 1.6 (1.1 to 2.4) 0.025
  10 to 19 mg/day 49 34.3 3.3 (2.2 to 4.8) <0.0001
  20+ mg/day 43 71.8 6.5(4.3 to 9.8) <0.0001
Cumulative prednisone dose None 29 13.1 1.0 (Ref. Gp)  
  <1 year (10 mg/day) 37 23.8 1.6 (1.0 to 2.6) 0.075
  1 to 3 years (10 mg/day) 30 19.0 1.8 (1.1 to 3.1) 0.026
  3 to 10 years (10 mg/day) 45 25.5 3.0 (1.8 to 5.2) <0.0001
  >10 years (10 mg/day) 9 24.3 3.7 (1.5 to 9.4) 0.0056
Current HCQ No 95 29.0 1.0 (Ref. Gp)  
  Yes 90 14.6 0.5 (0.4 to 0.7) <0.0001
HCQ use Never 57 32.2 1.0 (Ref. Gp)  
  Past (not current) 27 27.6 0.9 (0.6 to 1.5) 0.81
  <6 consecutive months 16 20.0 0.6 (0.3 to 1.0) 0.056
  >6 consecutive months 64 13.8 0.5 (0.3 to 0.7) 0.0003
NSAID use No 146 21.6 1.0 (Ref. Gp)  
  Yes 37 13.9 0.6 (0.4 to 0.9) 0.017
Aspirin use No 137 17.9 1.0 (Ref. Gp)  
  Yes 49 28.0 1.6 (1.2 to 2.3) 0.0038